Here are three insights:
1. The Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety Risk Management Advisory Committee approved the two drugs.
2. The panel voted 14 to 3 on Vantrela, and 9 to 6 on Troxyca.
3. Vantrela is an abuse-deterrent formulation of extended-release hydrocodone. Troxyca is an abuse-deterrent formulation of extended-release oxycodone with naltrexone.
More articles on quality & infection control:
NY legislation exempts drugstores from some patient safety standards: 5 things to know
Top 10 states with the highest & lowest ASC patient burn rates
FDA eases paperwork burden for experimental drugs — 5 notes
